MarketPulse

FDA-approved

4 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Mesoblast Limited

Mesoblast Plans First R&D Day to Showcase Pipeline, New Cell Therapy Tech

Mesoblast Limited will host inaugural R&D Day April 8, 2026 in NYC, featuring Ryoncil commercialization updates and new cellular medicine technology.
MESORyoncil®cellular medicines
GlobeNewswire Inc.GlobeNewswire Inc.··Mesoblast Limited

Mesoblast Taps Regeneron Veteran as Clinical Chief to Expand Cell Therapy Pipeline

Mesoblast appoints veteran biotech executive Dr. Teresa Montagut as Head of Clinical Development, signaling acceleration in cell therapy pipeline expansion and Ryoncil® indication broadening.
MESOclinical developmentRyoncil®
BenzingaBenzinga··Nabaparna Bhattacharya

Esperion Acquires Enbumyst Maker Corstasis for $75M in Cash-Plus-Milestone Deal

Esperion acquires Corstasis for $75M upfront plus $180M in milestones, gaining FDA-approved nasal spray diuretic Enbumyst for heart failure treatment.
ESPRacquisitionFDA-approved
GlobeNewswire Inc.GlobeNewswire Inc.··Na

ReWalk Exoskeleton Gains Aetna Coverage, Now Accessible Through Three Major Medicare Advantage Plans

Aetna approves Medicare Advantage coverage for ReWalk exoskeleton, expanding access to three major insurers serving 16 million beneficiaries and marking progress for wearable robotic technology reimbursement.
UNHLFWDHUMmedical deviceReWalk Personal Exoskeleton